Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from PolyPid ( (PYPD) ).
PolyPid Ltd. announced the appointment of Brooke Story as Chairman of the Board of Directors, effective December 11, 2025. With over 25 years of MedTech leadership experience, including senior roles at Becton, Dickinson and Company and Medtronic PLC, Story’s expertise in surgical markets and corporate strategy is expected to enhance PolyPid’s strategic, commercial, and transaction capabilities. This appointment comes at a crucial time as PolyPid prepares for the New Drug Application submission of D-PLEX100, potentially transforming its clinical success into commercial reality and creating significant enterprise value.
The most recent analyst rating on (PYPD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX technology, which enables precise drug delivery over extended periods. The company is preparing for the New Drug Application submission of its lead product candidate, D-PLEX100, aimed at preventing abdominal colorectal surgical site infections, expected in early 2026. PolyPid also has a pipeline in oncology, obesity, and diabetes.
Average Trading Volume: 81,493
Technical Sentiment Signal: Hold
Current Market Cap: $62.32M
For an in-depth examination of PYPD stock, go to TipRanks’ Overview page.